Lixte Biotech Hldgs (LIXT) 0.2500 $LIXT
Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors
Marketwire Canada - Tue Jun 07, 8:35AM CDT
EAST SETAUKET, NY--(Marketwired - Jun 7, 2016) - Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today the appointment of Stephen J. Forman, M.D., to the Board of Directors of Lixte. Dr. Forman is Director of the T cell Therapeutics Research Laboratory, Director of the Hematologic Malignancies and Stem Cell Transplantation Institute, and holds the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at the City of Hope National Medical Center in Duarte, California. He is co-editor of Thomas' Hematopoietic Cell Transplantation, a definitive textbook for clinicians, scientists and health care professionals.
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.05 (+0.33), OMER: 11.28 (-0.03), ATHX: 1.96 (-0.02), KPTI: 7.02 (-0.18), CUR: 0.27 (-0.02)
Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
Marketwired - Wed Feb 03, 9:00AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that neuroscientists at the French Institute of Health and Medical Research (Inserm) using a mouse model of depression have identified protein phosphatase 2A (PP2A) as a potential pharmacological target for therapy. Administration of LB-100, Lixte's proprietary inhibitor of PP2A, rapidly reduced depressive-like symptoms in these conditioned animals. The findings were published in the journal Nature Medicine on January 25th, 2016.
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.69 (+0.03), GSK: 44.36 (+0.04), CLBS: 5.58 (-0.30), MESO: 5.87 (+0.17), ATHX: 1.96 (-0.02), BXLT: 46.02 (-0.18)
Lixte Completes Private Placement of Convertible Preferred Stock
Marketwired - Mon Jan 25, 9:30AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common shares at a per share price of $0.80.
Neurofibromatoses Type II - Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/6h2l4j/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neurofibromatoses Type II Overview - Therapeutics Development - Pipeline Products for Neurofibromatoses Type II - Overview - Pipeline Products for Neurofibromatoses Type II - Comparative Analysis - Neurofibromatoses Type II - Therapeutics under Development by Companies - Neurofibromatoses Type II - Therapeutics under Investigation by Universities/Institutes - Neurofibromatoses Type II - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neurofibromatoses Type II - Products under Development by Companies - Neurofibromatoses Type II - Products under Investigation by Universities/Institutes - Neurofibromatoses Type II - Companies Involved in Therapeutics Development - Arno Therapeutics, Inc. - CalAsia Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Nexgenix Pharmaceuticals, LLC - Novartis AG For more information visit http://www.researchandmarkets.com/research/6h...bromatoses
NVS: 81.78 (+0.01)
Lixte Biotechnology Holdings grants exclusive licence of anti-cancer compound LB-100 to Taipei Medical University
M2 - Thu Dec 31, 6:31AM CST
Lixte Biotechnology Holdings Inc (OTCQB: LIXT) announced on Wednesday that it has granted an exclusive licence to Taipei Medical University (TMU), for Lixte's lead anti-cancer compound LB-100, to be used to treat hepatocellular carcinoma (HCC) in Asia.
Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University
PR Newswire - Wed Dec 30, 8:35AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not currently approved for treatment of HCC. Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed.
Septic Shock - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/pr4wsv/septic_shock) has announced the addition of the "Septic Shock - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Septic Shock's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope of the Report: - The report provides a snapshot of the global therapeutic landscape of Septic Shock - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Septic Shock and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Septic Shock pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Adrenomed AG - Ferring International Center S.A. - Huons Co., Ltd. - InflaRx GmbH - Lixte Biotechnology Holdings, Inc. - Noxxon Pharma AG - Orion Oyj - Peptinov SAS - Pharmazz, Inc. - Spider Biotech - Takeda Pharmaceutical Company Limited - XImmune AB For more information visit http://www.researchandmarkets.com/research/pr...ptic_shock
Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity
PR Newswire - Fri Nov 06, 11:30AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that in an ongoing Phase I trial its lead anti-cancer compound, LB-100, was associated with stabilization of a variety of advanced cancers that had been progressing despite extensive prior treatment. The results were presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, on November 6. The authors were Vincent Chung, City of Hope, Duarte, CA; Donald Richards, Texas Oncology, Tyler, TX; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; John S. Kovach, Lixte Biotechnology Holdings, Inc., East Setauket, NY; Aaron Scott Mansfield, Mayo Clinic, Rochester, MN.
Global Gaucher's Disease Pipeline Review, H2 2015 - 16 Companies & 20 Drug Profiles
M2 - Wed Oct 07, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hmwnzs/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Amicus Therapeutics, Inc. - Bioorganic Research and Services S.A. - Biosidus S.A. - Dong-A Socio Group - Genzyme Corporation - greenovation Biotech GmbH - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Lixte Biotechnology Holdings, Inc. - Neuraltus Pharmaceuticals, Inc. - Okklo Life Sciences BV - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - The International Biotechnology Center (IBC) Generium - UAB Profarma Drug Profiles - afegostat tartrate ERT - ambroxol - AT-3375 - BNT-001 - Gluco-Cerebosidase - GZ-402671 - imiglucerase biosimilar - LB-201 - LB-205 - miglustat - NP-003 - OKL-1014 - PRX-112 - Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases - Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease - Small Molecules to Inhibit Alpha-glucosidase for Diabetes and Gaucher's Disease - taliglucerase alfa For more information visit http://www.researchandmarkets.com/research/hm...rs_disease
FOLD: 6.88 (-0.12)
Lixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds
PR Newswire - Thu Sep 17, 12:00PM CDT
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) ("Lixte" or the "Company"
has engaged the services of BioPharmaWorks LLC ("BioPharmaWorks" to enhance the value of its clinical candidate portfolio. The scientific team at BioPharmaWorks (www.biopharmaworks.com) provides expertise in multiple aspects of drug discovery, development and intellectual property.
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Chronic Myelocytic Leukemia
M2 - Mon Aug 17, 8:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvnlhx/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AbbVie Inc. - Aprea AB - arGEN-X BV - Ariad Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Cantargia AB - Celgene Corporation - Constellation Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - Eisai Co., Ltd. - EpiZyme, Inc. - Galena Biopharma, Inc. - Gamida Cell Ltd. - Hybrigenics S.A. - Ilyang Pharmaceutical Co., Ltd - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Juno Therapeutics Inc. - JW Pharmaceutical Corporation - KaloBios Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Mirna Therapeutics, Inc. - Natco Pharma Limited - Novartis AG For more information visit http://www.researchandmarkets.com/research/fvnlhx/chronic
INCY: 76.94 (-0.92), EPZM: 8.78 (+0.24), BMY: 58.20 (-1.21), BPTH: 1.68 (unch), JUNO: 34.07 (-0.14), ABBV: 66.85 (+0.11), GALE: 0.40 (-0.01), NVS: 81.78 (+0.01), KPTI: 7.02 (-0.18), ARRY: 3.43 (-0.08), CELGZ: 1.11 (-0.12)
Neurofibromatoses Type II Therapeutics Pipeline Review 2015 - 4 Companies & 6 Drug Profiles
M2 - Thu Jun 25, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9gp7cv/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arno Therapeutics, Inc. - CalAsia Pharmaceuticals, Inc. - Nexgenix Pharmaceuticals, LLC - Lixte Biotechnology Holdings, Inc. Drug Profiles - AR-42 - FRAX-597 - LB-201 - LB-205 - NXD-30001 - Small Molecules to Inhibit Hsp90 for Neurofibromatosis Type 2 For more information visit http://www.researchandmarkets.com/research/9g...bromatoses
Septic Shock Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Tue Jun 16, 5:31AM CDT
The report "Septic Shock - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Septic Shock. Septic shock is life-threatening low blood pressure (shock) due to sepsis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Septic Shock with 30 market data tables and 14 figures, spread across 77 pages is available at http://www.rnrmarketresearch.com/septic-shock...eport.html .
CGEN: 6.71 (-0.06)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 2.05 (+0.33), CNCE: 10.95 (-0.06), ATHX: 1.96 (-0.02), KPTI: 7.02 (-0.18), CUR: 0.27 (-0.02)
Myocardial Ischemia - Pipeline Review, H1 2015 - 8 Companies & 22 Drug Profiles
M2 - Wed Mar 25, 12:05PM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc6lt6/myocardial) has announced the addition of the "Myocardial Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - CoDa Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Miltenyi Biotec GmbH - Nyken BV - Opsona Therapeutics Ltd. - Taxus Cardium Pharmaceuticals Group Inc. - ViroMed Co., Ltd. Drug Profiles - alferminogene tadenovec - AntimiR-199a - EP-80317 - Gene Therapy for Ischemic Heart Failure - Humanin - LB-100 - LB-102 - MG-53 - NYK-1112 - OPN-305 - Peptagon - PMC-6 - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology - Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Stem Cell Therapy for Cardiovascular Disease - Stem Cell Therapy for Cardiovascular Diseases - VM-202 For more information visit http://www.researchandmarkets.com/research/sc6lt6/myocardial
BAX: 47.83 (-0.41)
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
PR Newswire - Fri Jan 23, 8:04AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of clinical sites where its Phase I trial of Lixte's lead compound, LB--100, is being conducted, has been expanded from 1 to 5 institutions.
Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors
Marketwire Canada - Tue Jun 07, 8:35AM CDT
EAST SETAUKET, NY--(Marketwired - Jun 7, 2016) - Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today the appointment of Stephen J. Forman, M.D., to the Board of Directors of Lixte. Dr. Forman is Director of the T cell Therapeutics Research Laboratory, Director of the Hematologic Malignancies and Stem Cell Transplantation Institute, and holds the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at the City of Hope National Medical Center in Duarte, California. He is co-editor of Thomas' Hematopoietic Cell Transplantation, a definitive textbook for clinicians, scientists and health care professionals.
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.05 (+0.33), OMER: 11.28 (-0.03), ATHX: 1.96 (-0.02), KPTI: 7.02 (-0.18), CUR: 0.27 (-0.02)
Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
Marketwired - Wed Feb 03, 9:00AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that neuroscientists at the French Institute of Health and Medical Research (Inserm) using a mouse model of depression have identified protein phosphatase 2A (PP2A) as a potential pharmacological target for therapy. Administration of LB-100, Lixte's proprietary inhibitor of PP2A, rapidly reduced depressive-like symptoms in these conditioned animals. The findings were published in the journal Nature Medicine on January 25th, 2016.
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.69 (+0.03), GSK: 44.36 (+0.04), CLBS: 5.58 (-0.30), MESO: 5.87 (+0.17), ATHX: 1.96 (-0.02), BXLT: 46.02 (-0.18)
Lixte Completes Private Placement of Convertible Preferred Stock
Marketwired - Mon Jan 25, 9:30AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common shares at a per share price of $0.80.
Neurofibromatoses Type II - Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/6h2l4j/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neurofibromatoses Type II Overview - Therapeutics Development - Pipeline Products for Neurofibromatoses Type II - Overview - Pipeline Products for Neurofibromatoses Type II - Comparative Analysis - Neurofibromatoses Type II - Therapeutics under Development by Companies - Neurofibromatoses Type II - Therapeutics under Investigation by Universities/Institutes - Neurofibromatoses Type II - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neurofibromatoses Type II - Products under Development by Companies - Neurofibromatoses Type II - Products under Investigation by Universities/Institutes - Neurofibromatoses Type II - Companies Involved in Therapeutics Development - Arno Therapeutics, Inc. - CalAsia Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Nexgenix Pharmaceuticals, LLC - Novartis AG For more information visit http://www.researchandmarkets.com/research/6h...bromatoses
NVS: 81.78 (+0.01)
Lixte Biotechnology Holdings grants exclusive licence of anti-cancer compound LB-100 to Taipei Medical University
M2 - Thu Dec 31, 6:31AM CST
Lixte Biotechnology Holdings Inc (OTCQB: LIXT) announced on Wednesday that it has granted an exclusive licence to Taipei Medical University (TMU), for Lixte's lead anti-cancer compound LB-100, to be used to treat hepatocellular carcinoma (HCC) in Asia.
Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University
PR Newswire - Wed Dec 30, 8:35AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not currently approved for treatment of HCC. Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed.
Septic Shock - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/pr4wsv/septic_shock) has announced the addition of the "Septic Shock - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Septic Shock's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope of the Report: - The report provides a snapshot of the global therapeutic landscape of Septic Shock - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Septic Shock and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Septic Shock pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Adrenomed AG - Ferring International Center S.A. - Huons Co., Ltd. - InflaRx GmbH - Lixte Biotechnology Holdings, Inc. - Noxxon Pharma AG - Orion Oyj - Peptinov SAS - Pharmazz, Inc. - Spider Biotech - Takeda Pharmaceutical Company Limited - XImmune AB For more information visit http://www.researchandmarkets.com/research/pr...ptic_shock
Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity
PR Newswire - Fri Nov 06, 11:30AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that in an ongoing Phase I trial its lead anti-cancer compound, LB-100, was associated with stabilization of a variety of advanced cancers that had been progressing despite extensive prior treatment. The results were presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, on November 6. The authors were Vincent Chung, City of Hope, Duarte, CA; Donald Richards, Texas Oncology, Tyler, TX; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; John S. Kovach, Lixte Biotechnology Holdings, Inc., East Setauket, NY; Aaron Scott Mansfield, Mayo Clinic, Rochester, MN.
Global Gaucher's Disease Pipeline Review, H2 2015 - 16 Companies & 20 Drug Profiles
M2 - Wed Oct 07, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hmwnzs/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Amicus Therapeutics, Inc. - Bioorganic Research and Services S.A. - Biosidus S.A. - Dong-A Socio Group - Genzyme Corporation - greenovation Biotech GmbH - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Lixte Biotechnology Holdings, Inc. - Neuraltus Pharmaceuticals, Inc. - Okklo Life Sciences BV - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - The International Biotechnology Center (IBC) Generium - UAB Profarma Drug Profiles - afegostat tartrate ERT - ambroxol - AT-3375 - BNT-001 - Gluco-Cerebosidase - GZ-402671 - imiglucerase biosimilar - LB-201 - LB-205 - miglustat - NP-003 - OKL-1014 - PRX-112 - Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases - Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease - Small Molecules to Inhibit Alpha-glucosidase for Diabetes and Gaucher's Disease - taliglucerase alfa For more information visit http://www.researchandmarkets.com/research/hm...rs_disease
FOLD: 6.88 (-0.12)
Lixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds
PR Newswire - Thu Sep 17, 12:00PM CDT
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) ("Lixte" or the "Company"
has engaged the services of BioPharmaWorks LLC ("BioPharmaWorks" to enhance the value of its clinical candidate portfolio. The scientific team at BioPharmaWorks (www.biopharmaworks.com) provides expertise in multiple aspects of drug discovery, development and intellectual property. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Chronic Myelocytic Leukemia
M2 - Mon Aug 17, 8:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvnlhx/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AbbVie Inc. - Aprea AB - arGEN-X BV - Ariad Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Cantargia AB - Celgene Corporation - Constellation Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - Eisai Co., Ltd. - EpiZyme, Inc. - Galena Biopharma, Inc. - Gamida Cell Ltd. - Hybrigenics S.A. - Ilyang Pharmaceutical Co., Ltd - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Juno Therapeutics Inc. - JW Pharmaceutical Corporation - KaloBios Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Mirna Therapeutics, Inc. - Natco Pharma Limited - Novartis AG For more information visit http://www.researchandmarkets.com/research/fvnlhx/chronic
INCY: 76.94 (-0.92), EPZM: 8.78 (+0.24), BMY: 58.20 (-1.21), BPTH: 1.68 (unch), JUNO: 34.07 (-0.14), ABBV: 66.85 (+0.11), GALE: 0.40 (-0.01), NVS: 81.78 (+0.01), KPTI: 7.02 (-0.18), ARRY: 3.43 (-0.08), CELGZ: 1.11 (-0.12)
Neurofibromatoses Type II Therapeutics Pipeline Review 2015 - 4 Companies & 6 Drug Profiles
M2 - Thu Jun 25, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9gp7cv/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arno Therapeutics, Inc. - CalAsia Pharmaceuticals, Inc. - Nexgenix Pharmaceuticals, LLC - Lixte Biotechnology Holdings, Inc. Drug Profiles - AR-42 - FRAX-597 - LB-201 - LB-205 - NXD-30001 - Small Molecules to Inhibit Hsp90 for Neurofibromatosis Type 2 For more information visit http://www.researchandmarkets.com/research/9g...bromatoses
Septic Shock Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Tue Jun 16, 5:31AM CDT
The report "Septic Shock - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Septic Shock. Septic shock is life-threatening low blood pressure (shock) due to sepsis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Septic Shock with 30 market data tables and 14 figures, spread across 77 pages is available at http://www.rnrmarketresearch.com/septic-shock...eport.html .
CGEN: 6.71 (-0.06)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 2.05 (+0.33), CNCE: 10.95 (-0.06), ATHX: 1.96 (-0.02), KPTI: 7.02 (-0.18), CUR: 0.27 (-0.02)
Myocardial Ischemia - Pipeline Review, H1 2015 - 8 Companies & 22 Drug Profiles
M2 - Wed Mar 25, 12:05PM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc6lt6/myocardial) has announced the addition of the "Myocardial Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - CoDa Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Miltenyi Biotec GmbH - Nyken BV - Opsona Therapeutics Ltd. - Taxus Cardium Pharmaceuticals Group Inc. - ViroMed Co., Ltd. Drug Profiles - alferminogene tadenovec - AntimiR-199a - EP-80317 - Gene Therapy for Ischemic Heart Failure - Humanin - LB-100 - LB-102 - MG-53 - NYK-1112 - OPN-305 - Peptagon - PMC-6 - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology - Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Stem Cell Therapy for Cardiovascular Disease - Stem Cell Therapy for Cardiovascular Diseases - VM-202 For more information visit http://www.researchandmarkets.com/research/sc6lt6/myocardial
BAX: 47.83 (-0.41)
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
PR Newswire - Fri Jan 23, 8:04AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of clinical sites where its Phase I trial of Lixte's lead compound, LB--100, is being conducted, has been expanded from 1 to 5 institutions.
